(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "reasonably predict" clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.
Contents:
Part I. Chemopreventive Agent Development Science
Characterization of Natural Product Chemopreventive Agents
John M. Pezzuto, Jerome W. Kosmeder II, Eun-Jung Park, Sang Kook Lee, Muriel Cuendet, Joell Gills, Krishna Bhat, Simonida Grubjesic, Hye-Sung Park, Eugenia Mata-Greenwood, YingMeei Tan, Rong Yu, Daniel D. Lantvit, and A. Douglas Kinghorn
Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs
Vernon E. Steele, Ronald A. Lubet, and Richard C. Moon
Potential Use of Transgenic Mice in Chemoprevention Studies
Ronald A. Lubet, Jeffrey Green, Vernon E. Steele, and Ming You
Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies
Martin Lipkin and Sergio A. Lamprecht
Pathology of Incipient Neoplasia
Donald Earl Henson and Jorge Albores-Saavedra
Quantitative Nuclear Grade: Clinical Applications of the Quantitative Measurement of Nuclear Structure Using Image Analysis
Robert W. Veltri, Alan W. Partin, and M. Craig Miller
Enabling Discovery Through Online Cancer Genome Databases and Analytic Tools
Robert L. Strausberg and Gregory J. Riggins
Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention
Melissa A. Troester and Charles M. Perou
Clinical Applications of Proteomics
Emanuel F. Petricoin III and Lance A. Liotta
Bioinformatics and Whole-Genome Technologies
Richard Simon
Models of Absolute Risk: Uses, Estimation, and Validation
Mitchell H. Gail
Genetic Polymorphisms and Risk Assessment for Cancer Chemoprevention
Sonia de Assis and Peter G. Shields
Design Issues in Prostate Cancer Chemoprevention Trials: Lessons From the Prostate Cancer Prevention Trial
Ian M. Thompson and Charles A. Coltman Jr.
Recruitment Strategies for Cancer Prevention Trials
Paul P. Carbone, Karen Sielaff, Mary Hamielec, and Howard Bailey
Part II. Cancer Chemoprevention at Major Cancer Target Sites
Prostate
Prostate Cancer Prevention
William G. Nelson, Angelo M. de Marzo, and Scott M. Lippman
Use of PSA to Evaluate Risk and Progression of Prostate Cancer
Bulent Akduman, Abelardo Errejon, and E. David Crawford
Breast
Clinical Approaches to Discovering and Testing New Breast Cancer Prevention Drugs
Carol J. Fabian, Bruce F. Kimler, Matthew S. Mayo, William E. Grizzle, Shahla Masood, and Giske Ursin
Ductal Lavage: Its Role in Breast Cancer Risk Assessment and Risk Reduction
Joyce O'Shaughnessy and Andrea Decensi
Counteracting Estrogen as Breast Cancer Prevention
Kathrin Strasser-Weippl and Paul E. Goss
Colorectal
Chemoprevention of Colorectal Cancer: Clinical Strategies
Monica M. Bertagnolli and Stanley R. Hamilton
Screening in Risk Evaluation and Prevention of Colorectal Cancer
Bernard Levin
Lung
Strategies in Lung Cancer Chemoprevention
Edward S. Kim, Faye M. Johnson, Waun Ki Hong, and Fadlo R. Khuri
Lung Cancer Chemoprevention: An Opportunity for Direct Drug Delivery
James L. Mulshine and Luigi M. De Luca
Bladder
Bladder Cancer: Clinical Strategies for Cancer Chemoprevention
H. Barton Grossman, Anita L. Sabichi, and Yu Shen
Esophagus
Barrett's Esophagus: Strategies for Cancer Prevention
Brian J. Reid
Endoscopic Detection of Esophageal Neoplasia
Brian C. Jacobson and Jacques Van Dam
Chemoprevention Strategies for Esophageal Squamous Cell Carcinoma
Paul J. Limburg, Philip R. Taylor, and Sanford M. Dawsey
Head and Neck
Chemoprevention of Upper Aerodigestive Tract Cancer: Clinical Trials and Future Directions
Fadlo R. Khuri, Edward S. Kim, and Waun Ki Hong
Chemoprevention of Oral Cancer: Ri
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2014
Pages: 576
Weight: 1433g
Availability: Available
Subcategories: Oncology
From the same series
